Arnhold LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Arnhold LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 16.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 758,746 shares of the biopharmaceutical company's stock after purchasing an additional 106,267 shares during the period. Pfizer comprises 2.0% of Arnhold LLC's holdings, making the stock its 17th largest position. Arnhold LLC's holdings in Pfizer were worth $20,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Pingora Partners LLC lifted its position in shares of Pfizer by 24.6% in the fourth quarter. Pingora Partners LLC now owns 84,718 shares of the biopharmaceutical company's stock valued at $2,248,000 after acquiring an additional 16,748 shares in the last quarter. Cheviot Value Management LLC lifted its holdings in Pfizer by 5.9% in the 4th quarter. Cheviot Value Management LLC now owns 440,622 shares of the biopharmaceutical company's stock valued at $11,690,000 after purchasing an additional 24,562 shares in the last quarter. Voya Financial Advisors Inc. lifted its holdings in Pfizer by 4.7% in the 4th quarter. Voya Financial Advisors Inc. now owns 41,288 shares of the biopharmaceutical company's stock valued at $1,091,000 after purchasing an additional 1,841 shares in the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of Pfizer by 0.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 492,149 shares of the biopharmaceutical company's stock worth $13,057,000 after buying an additional 3,392 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. raised its position in shares of Pfizer by 32.3% in the fourth quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,253,756 shares of the biopharmaceutical company's stock valued at $33,364,000 after buying an additional 305,889 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. UBS Group cut their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $29.57.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Pfizer Stock Up 0.7 %

Shares of NYSE PFE traded up $0.17 during midday trading on Friday, hitting $22.95. The company's stock had a trading volume of 35,816,572 shares, compared to its average volume of 40,530,268. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $130.16 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business's fifty day simple moving average is $24.58 and its two-hundred day simple moving average is $25.94. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.49%. Pfizer's dividend payout ratio (DPR) is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.